Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019
Cited by 288 works. doi:10.1016/s1470-2045(18)30791-5
Authors
- Charles S. Fuchs
- Kohei Shitara
- Maria Di Bartolomeo
- Sara Lonardi
- Salah‐Eddin Al‐Batran
- Eric Van Cutsem
- David H. Ilson
- María Alsina
- Ian Chau
- Jill Lacy
- Michel Pierre Ducreux
- Guillermo Ariel Mendez
- Alejandro Molina Alavez
- Daisuke Takahari
- Wasat Mansoor
- Peter C. Enzinger
- Vera A. Gorbounova
- Zev A. Wainberg
- Susanna Hegewisch‐Becker
- David Raymond Ferry
References
- Global cancer statistics
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- Global cancer statistics, 2012
- Angiogenesis in cancer and other diseases
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- Chemotherapy for advanced gastric cancer
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up